UNITE4TB

🚀 Exciting Milestone! UNITE4TB has successfully completed participant recruitment for its DECISION trial. This pivotal Phase 2B study is set to evaluate the safety and efficacy of the novel antibiotic BTZ-043 for drug-sensitive TB. Kudos to our dedicated team and partners for their hard work and commitment to advancing TB treatment. 🌍💊 Learn more about this latest milestone and its potential impact 👉 https://lnkd.in/e3ccJdT9 #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator, LMU Munich – Ludwig-Maximilians-Universität München, LMU Klinikum München, Michael Hoelscher, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research

Happening soon! Don't forget to join our #webinar today starting at 13:00 (CEST). More info and the link to register below 👇

Our latest UNITE4TB Newsletter is out, packed with updates and insights on our ongoing efforts to accelerate the development of new treatment regimens for tuberculosis (TB). Here’s a sneak peek at what’s inside: 🔹 2024 Annual Consortium Meeting & Joint Symposium with ERA4TB: Highlights and key takeaways from this event, emphasizing the importance of collaborative efforts in TB research. 🔹 World TB Day Activities: A look back at our activities to mark this year's awareness day. 🔹 Upcoming UNITE4TB webinar: Join us on 27 June for an in-depth discussion on approaches to market-shaping and access to TB medicines. 🔹 Publications: New publications from the UNITE4TB Consortium 🔗👉 https://lnkd.in/esEEiJjc Subscribe to our newsletter for the latest news and updates (see link in comments) #UNITE4TB #EndTB #Newsletter #SubscribeNow #GlobalHealth #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator.

📢 Registration open for the next UNITE4TB #webinar: Expert interview: an approach to market-shaping and access to TB medicines Date: 27 June, 13:00–14:00 CEST Find out more and register 👉 https://lnkd.in/eHtCUM3Y ISPUP | Instituto de Saúde Pública da Universidade do Porto, European Respiratory Society Innovative Health Initiative (IHI) AMR Accelerator

The 2024 UNITE4TB Consortium Meeting took place in Uppsala, Sweden on 16-17 May, preceded by our first-ever Joint Symposium with ERA4TB on 15 May. The three days generated many valuable insights and lively scientific discussions, providing attendees with a solid overview of the current status of both projects and our ambitions for the future. Special thanks to our hosts, Uppsala University! We're happy to share our post-event summary, with a selection of images from all three days 👉 https://lnkd.in/eCy5Adfj #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator. Radboudumc, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, Oxford University Clinical Research Unit, Research Center Borstel, Lygature, Lancaster University, UCL, MRC Clinical Trials Unit at UCL, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, University of Hamburg, University of California, San Francisco, TB Alliance, FIND, Università degli Studi di Milano, Centre Multidisciplinary Research in Health Science , School of Medicine, University of St Andrews, University of St Andrews, Farmaceutiska fakulteten • Uppsala universitet, European Respiratory Society, TBnet, GSK, Johnson & Johnson, Ludwig-Maximilians-Universität München, LMU Klinikum München, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research

📢 Two recent publications coming out of the UNITE4TB Consortium: 1. Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles Source: The Lancet, Microbe 👉 https://lnkd.in/e-zeujXQ "A big effort by the UNITE4TB biomarker team, which will aid future early- and late-stage drug trials and ultimately enable shorter, faster trials with biomarker endpoints," said contributing author and Consortium member, Morten Ruhwald, MD, PhD, Director of TB Programme at FIND. School of Medicine, University of St Andrews, Radboudumc, Ludwig-Maximilians-Universität München, LMU Klinikum München, FIND, German Center for Infection Research, Research Center Borstel, Johnson & Johnson, University of Oxford, Oxford University Clinical Research Unit. 2. Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis Source: BMJ Global Health, Volume 9, Issue 4 👉 https://lnkd.in/ekHiNyRg This study was carried out by the Centre Multidisciplinary Research in Health Science team at the Università degli Studi di Milano, part of the UNITE4TB Consortium. It discusses #tuberculosis (TB) research and development and the gaps that exist in terms of access to emerging #TB innovations in low- and middle-income countries with high TB burden. #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator.

That’s a wrap for the 2024 UNITE4TB Annual Meeting, kindly hosted by our Consortium Partner Uppsala University.   Closing the meeting, UNITE4TB project lead Derek Sloan (Radboudumc) thanked everyone for their participation and contributions and noted that it’s inspiring and reassuring to see how we are moving forward: "The symposium with ERA4TB provided thought-provoking scientific discussions with a true spirit of joint engagement. UNITE4TB is continuing to build its engine. Our challenge in the coming years is to fully construct this engine and to keep working in a balanced way that makes full use of the multi-disciplinary skillset of the consortium. We will strive to move forward better together."   #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator.  

Day 2 of the 2024 UNITE4TB Annual Meeting begins. Today, Tek-Ang Lim (Scientific Officer, Innovative Health Initiative (IHI)) gives a run-down of the IHI Interim Review for UNITE4TB and we hear from our Advisory Boards (Scientific, Ethics, and Community Boards) as well as our Young Investigators Group.   We also have a panel discussion about responding to the emerging threat of bedaquiline resistance moderated by Christoph Lange (Research Center Borstel) with speakers from TASK (Caryn Upton), Institute of Tropical Medicine Antwerp (Bouke de Jong), The Janssen Pharmaceutical Companies of Johnson & Johnson (Vivian Cox), and the TB Unit Lead of the World Health Organization Regional Office for Europe (Askar Yedilbayev).   Lots to come. It’s sure to be a good one!   #PublicPrivatePartnership #YesWeCanEndTB EFPIA - European Federation of Pharmaceutical Industries and Associations; German Center for Infection Research; Ludwig-Maximilians-Universität München; LMU Klinikum München; AMR Accelerator, Uppsala University, Farmaceutiska fakulteten • Uppsala universitet

Day 1 of our 2024 Annual Meeting has come to a close. Following a warm welcome by UNITE4TB Project Lead, Derek Sloane (Radboudumc), Tek-Ang Lim (Scientific Officer at Innovative Health Initiative (IHI)) spoke on maximizing UNITE4TB’s impact. In addition to updates from all 12 Work Packages, we also had several break-out sessions, such as one on how to ensure equitable access to UNITE4TB innovations with speakers from the World Health Organization, the European Medicines Agency, TB Alliance, GSK, and the Global Drug Facility (Stop TB Partnership). The session was organized by UNITE4TB’s stakeholder management team led by Università degli Studi di Milano. Finally, we closed the day with a presentation by our keynote speaker, Rada Savic of the University of California, San Francisco, who spoke on intelligence for accelerating and de-risking TB regimen development.   More to come tomorrow!   Radboudumc, Lygature, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, European Respiratory Society, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, FIND, Uppsala University, UCL, MRC Clinical Trials Unit at UCL, University of St Andrews, Research Center Borstel, Lancaster University, University of Hamburg, University of California, San Francisco, TBnet, Johnson & Johnson, LMU Klinikum München, German Center for Infection Research, EFPIA - European Federation of Pharmaceutical Industries and Associations, AMR Accelerator   📷 Judith Eckstein

Our 2024 UNITE4TB Annual Consortium Meeting is underway! Following our Joint Symposium with ERA4TB yesterday, we’re staying in Sweden as our Consortium Partner Uppsala University kindly hosts this year’s event. Over the next two days, updates will be provided on the overall status of the project, the achievements made to date, and the plans for the next year.   We’re looking forward to fruitful discussions that help pave the way to better, safer, more affordable treatment solutions for those affected by tuberculosis. In the meantime, we’re pleased to share some impressions of our Joint Symposium with ERA4TB yesterday 👇 #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator.   Radboudumc, Radboudumc Research, Lygature, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, Oxford University Clinical Research Unit, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, European Respiratory Society, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, TB Alliance, FIND, Università degli Studi di Milano, Uppsala University, Farmaceutiska fakulteten • Uppsala universitet, UCL, MRC Clinical Trials Unit at UCL, University of St Andrews, Research Center Borstel, Lancaster University, University of Hamburg, University of California, San Francisco, TBnet, GSK, Johnson & Johnson, Ludwig-Maximilians-Universität München, LMU Klinikum München, German Center for Infection Research, EFPIA - European Federation of Pharmaceutical Industries and Associations.